| dc.contributor.author | Hussain, SA | en |
| dc.contributor.author | Birtle, A | en |
| dc.contributor.author | Crabb, S | en |
| dc.contributor.author | Huddart, R | en |
| dc.contributor.author | Small, D | en |
| dc.contributor.author | Summerhayes, M | en |
| dc.contributor.author | Jones, R | en |
| dc.contributor.author | Protheroe, A | en |
| dc.date.accessioned | 2022-01-18T14:16:53Z | |
| dc.date.issued | 2018-12 | en |
| dc.identifier.issn | 2588-9311 | en |
| dc.identifier.uri | http://hdl.handle.net/10026.1/18580 | |
| dc.format.extent | 486 - 500 | en |
| dc.language | en | en |
| dc.language.iso | en | en |
| dc.publisher | Elsevier | en |
| dc.title | From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma | en |
| dc.type | Journal Article | |
| plymouth.issue | 6 | en |
| plymouth.volume | 1 | en |
| plymouth.journal | European Urology Oncology | en |
| dc.identifier.doi | 10.1016/j.euo.2018.05.011 | en |
| plymouth.organisational-group | /Plymouth | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
| dcterms.dateAccepted | 2018-05-30 | en |
| dc.rights.embargodate | 2022-01-19 | en |
| dc.rights.embargoperiod | Not known | en |
| rioxxterms.versionofrecord | 10.1016/j.euo.2018.05.011 | en |
| rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | en |
| rioxxterms.licenseref.startdate | 2018-12 | en |
| rioxxterms.type | Journal Article/Review | en |
